Magic Medical has received hundreds of millions of yuan in Series C financing, and there is still a lot of room for development in the domestic drug balloon market.

Shanghai Shenqi Medical Technology Co., Ltd. (hereinafter referred to as Shenqi Medical) has completed several hundred million yuan of Series C financing on August 24th. The financing was led by Gaoling Venture Capital and Jifeng Capital, with Sanzheng Health Investment and Xingze Capital as the old shareholders, and Dianshi Capital as the exclusive financial advisor. This round of financing is mainly used to promote R&D and existing products, test R&D and new projects, and accelerate product promotion and industrialization.

Two months ago, Magic Medical just completed a series B financing of several hundred million yuan, which was invested by Sanzheng Health and Pu Tian Assets. Last June, 5438+065438+ 10, Xingze Capital completed tens of millions of RMB Series A financing.

Magic Medical was established in September 2065438+2004. Is a high-tech medical equipment enterprise integrating R&D, production and sales, focusing on the field of high-value consumables. The products involve cardiovascular intervention, peripheral vascular intervention, neurovascular intervention and structural heart disease. Among them, the drug-coated coronary balloon catheter obtained NMPA registration certificate in February 20 19, and it is the second enterprise to obtain NMPA certification for drug balloon products. Another left atrial appendage occluder product is in the clinical trial stage and is expected to be available at the end of 2002/kloc-0.

Dai Zhihao, the founder of Shenqi Medical, graduated from Shanghai Medical University (now Fudan University) and has more than 20 years of professional experience in the industry. Magic Medical has a group of professionals engaged in R&D and implantable medical devices production, and the core members of the team have the working experience of American medical device companies and leading domestic medical device companies.

In 20 19, in the field of cardiovascular interventional surgery in China, the overall use ratio of drug balloons (80,000) only accounts for 4% of stents (2 million). Compared with the foreign ratio of 15%, the domestic drug balloon market still has great room for development.

At present, many pathological types are using drug balloons. The mixed matrix of paclitaxel with high lipophilicity and iopromide with high hydrophilicity is loaded on a balloon, delivered to a narrow blood vessel through a guide wire, quickly inflated to open the stenosis, and then quickly deflated and withdrawn. Drugs can enter the local tissue of blood vessels in a short time to achieve the effect of inhibiting proliferation.

As a new method of coronary intervention, drug balloon does not need to implant foreign bodies compared with traditional stent implantation, which can reduce intimal inflammation and has no risk of stent thrombosis. In addition, dual antiplatelet drugs need to be taken for one year after stent implantation, and drug balloon therapy can greatly shorten the taking time to 1-3 months and reduce bleeding complications. If the price is too high, blood vessels may be torn and dissected during the operation. At this time, the stent must be implanted, and the drug balloon is not suitable for all lesions, which is its shortcoming. However, drug balloon therapy has a good effect and a good prognosis, especially for young patients and patients with high risk of bleeding.

For the success of this financing, Dai Zhihao, the founder of Magic Medical, said: "The past five years have only been the first step taken by Magic Medical. In the future, magic medical care will closely focus on the development of high-value medical device consumables. We hope to become a first-class competitive enterprise in the fields of vascular intervention, structural heart disease treatment and heart failure management. "

Yi Nuoqing, co-chief investment officer of Gaochun Capital and head of biomedical and medical devices of Gaochun Venture Capital, said: "Biomedicine and medical devices have always been the key areas of Gaochun's layout. Magic Medical is positioned as a platform company in the field of intervention, with profound technology accumulation, reasonable product layout and strong team execution. "

Jifeng Capital LYFE Capital is a professional Sino-American medical fund with assets of about US$ 654.38+300 million. Partner Chen Gang thinks: "Magic Medical has high-quality and high-tech products, fast and efficient R&D registration and industrialization system and strong commercialization capability. Team members have rich experience in cardiovascular product development and sales. "